Antiangiogenic therapies for advanced hepatocellular carcinoma.
about
Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinomaSorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in JapanPrognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma.Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.Downregulation of tetrahydrobiopterin inhibits tumor angiogenesis in BALB/c-nu mice with hepatocellular carcinoma.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF.Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma.Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance.Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance.Identifying molecular targets to improve immune function in alcoholic hepatitis.Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications.
P2860
Q28829736-E303D5C9-9E8C-4AA6-BBF0-EC56ED58CC78Q33794350-8FE691ED-0005-407A-BEF4-381791F9785CQ35274662-F9C0CB26-700F-4822-8B03-26BE82E7B61CQ36097965-D59BDB74-DDF5-4375-85DC-FA95D9B30657Q37066679-0440569F-1C06-4C4F-8546-7B973426C18FQ37262768-92692D4B-9BE4-48FD-B671-278C357381EAQ37327584-71C812D0-AB49-4AA8-AB18-5E913A9CE4A1Q37731561-D39CA720-DE70-477B-9F7D-D1D8B613B89EQ38702727-4BA663B1-CB80-4DE2-B9A5-36E7CDA50564Q38827855-248753BE-5E80-4464-ADB8-7B0A40512D44Q38948950-79C375E9-4AD4-4F9A-AA18-1930818B1A3CQ42376719-C8C3A660-476F-443C-9A5C-13AE65620103Q42586709-DA476AB4-797F-4187-ACF8-BC0985AD6909Q47266310-5DC7E69D-7B7F-44C7-BBAD-CED813422913Q52982362-7392FE2C-2268-4F18-B081-6ABB3559D810Q55618701-2C69C2E4-DB4E-424B-B17E-5DDE20FB026E
P2860
Antiangiogenic therapies for advanced hepatocellular carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@ast
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@en
type
label
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@ast
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@en
prefLabel
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@ast
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@en
P2860
P1433
P1476
Antiangiogenic therapies for advanced hepatocellular carcinoma.
@en
P2093
Bert O'Neil
Keeran R Sampat
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0388
P577
2013-04-10T00:00:00Z